SCHEMBL4359143

SCHEMBL4359143

CS(=O)(=O)N1CCC(Nc2ncc(C(=O)c3c(O)c(O)cc(F)c3F)c(N)n2)CC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 19/20 0.74
CCND1 P24385 16/20 0.74
CDK1 P06493 15/20 0.74
CDK4 P11802 14/20 0.74
CDK6 Q00534 4/20 0.72
CDK5 Q00535 2/20 0.72
CASK O14936 1/20 0.72
ROCK2 O75116 1/20 0.72
CDKL5 O76039 1/20 0.72
STK10 O94804 1/20 0.72
CDK14 O94921 1/20 0.72
ABL1 P00519 1/20 0.72
EGFR P00533 1/20 0.72
MAK P20794 1/20 0.72
CDK11B P21127 1/20 0.72
TTK P33981 1/20 0.72
CLK1 P49759 1/20 0.72
CLK2 P49760 1/20 0.72
CLK3 P49761 1/20 0.72
GSK3A P49840 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352866 0.91 CDK1 (0.85) CDK2CCND1CDK1CDK4CDK6
SCHEMBL4361166 0.91 CDK1 (0.78) CDK2CCND1CDK1CDK4CDK6
SCHEMBL4348415 0.89 CDK2 (0.80) CDK2CCND1CDK1CDK4CDK6
SCHEMBL3526252 0.87 CDK2 (0.73) CDK2CCND1CDK1CDK4CDK6
SCHEMBL4347367 0.85 CDK1 (0.85) CDK2CCND1CDK1CDK4CDK6
SCHEMBL4360093 0.85 CDK1 (1.00) CDK2CCND1CDK1CDK4CDK6
SCHEMBL3522558 0.85 CDK1 (1.00) CDK2CCND1CDK1CDK4CDK6
SCHEMBL3520595 0.85 CDK1 (0.79) CDK2CCND1CDK1CDK4CDK6
SCHEMBL13621443 0.85 CDK1 (0.79) CDK2CCND1CDK1CDK4CDK6
SCHEMBL3519522 0.85 CDK2 (0.68) CDK2CCND1CDK1CDK4CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK2 4/4885CCND1 32/4885CDK1 6/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK2 3/4885CCND1 31/4885CDK1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.